Europe Approves Bristol Myers' Cell Therapy Breyanzi For Patients With Certain Type Of Blood Cancer
EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...
Bristol-Myers Squibb (NYSE:BMY) Gets EC Nod For Breyanzi In NHL Treatment
Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...
Precision Medicine Online11h
BMS's Breyanzi Gains European Approval as Third-Line Treatment for Follicular Lymphoma
The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.
Investing.com Australia16h
European Commission expands approval for Bristol Myers Squibb’s lymphoma therapy
Investing.com -- The European Commission has granted Bristol Myers (NYSE: BMY) Squibb, the biopharmaceutical company based in ...
Le Lézard17h
Baron Evans of Sealand and PR Guru Paul Holmes to Lead Davos Communications Summit 2025 on April 10 in Switzerland
Two of the most influential voices in strategic communication ? Baron Evans of Sealand and Paul Holmes, will take center stage at the Davos Communications Summit & Awards 2025 on April 10 at the Davos ...
Bristol Myers Gets Expanded European Approval for Breyanzi
Bristol Myers Squibb has won European Commission expanded approval of its CAR-T cell therapy Breyanzi in the blood cancer lymphoma.
Bristol Myers announces EC approval of Breyanzi
Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T ...
Le Lézard17h
Life Time Launches All-New 60XT Challenge with $200,000 in Grand Prizes on the Line, Including $10K Cash for Top Five Finishers
Life Time  is launching an all-new challenge, 60XT, just in time to transform for summer. The Challenge kicks off March 24, and registration is now open via the Life Time app or in club for the ...